PMC:7408073 / 58823-59332 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T382","span":{"begin":124,"end":129},"obj":"Body_part"},{"id":"T383","span":{"begin":483,"end":488},"obj":"Body_part"}],"attributes":[{"id":"A382","pred":"fma_id","subj":"T382","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A383","pred":"fma_id","subj":"T383","obj":"http://purl.org/sig/ont/fma/fma9670"}],"text":"Although ACE2 pathway inhibition might lead to hypertensive effects, treatment with MLN-4760 for 4-5 weeks had no effect on blood pressure when administered 10 mg/kg/day in drinking water in wild type mice [117] nor in male (mRen2)27 transgenic hypertensive rats (administered 30 mg/kg/day subcutaneously via mini-osmotic pumps) [118], suggesting that hypertensive activity mediated by ACE2 inhibition is promptly balanced by compensatory mechanisms either in normal or hypertensive blood pressure conditions."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T123","span":{"begin":124,"end":129},"obj":"Body_part"},{"id":"T124","span":{"begin":483,"end":488},"obj":"Body_part"}],"attributes":[{"id":"A123","pred":"uberon_id","subj":"T123","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A124","pred":"uberon_id","subj":"T124","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"Although ACE2 pathway inhibition might lead to hypertensive effects, treatment with MLN-4760 for 4-5 weeks had no effect on blood pressure when administered 10 mg/kg/day in drinking water in wild type mice [117] nor in male (mRen2)27 transgenic hypertensive rats (administered 30 mg/kg/day subcutaneously via mini-osmotic pumps) [118], suggesting that hypertensive activity mediated by ACE2 inhibition is promptly balanced by compensatory mechanisms either in normal or hypertensive blood pressure conditions."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2121","span":{"begin":9,"end":13},"obj":"Gene"},{"id":"2122","span":{"begin":386,"end":390},"obj":"Gene"},{"id":"2128","span":{"begin":84,"end":87},"obj":"Gene"},{"id":"2131","span":{"begin":201,"end":205},"obj":"Species"},{"id":"2132","span":{"begin":258,"end":262},"obj":"Species"},{"id":"2135","span":{"begin":234,"end":244},"obj":"Species"},{"id":"2136","span":{"begin":182,"end":187},"obj":"Chemical"},{"id":"2139","span":{"begin":47,"end":59},"obj":"Disease"},{"id":"2140","span":{"begin":245,"end":257},"obj":"Disease"},{"id":"2141","span":{"begin":352,"end":364},"obj":"Disease"},{"id":"2142","span":{"begin":470,"end":482},"obj":"Disease"}],"attributes":[{"id":"A2121","pred":"tao:has_database_id","subj":"2121","obj":"Gene:70008"},{"id":"A2122","pred":"tao:has_database_id","subj":"2122","obj":"Gene:302668"},{"id":"A2128","pred":"tao:has_database_id","subj":"2128","obj":"Gene:69563"},{"id":"A2131","pred":"tao:has_database_id","subj":"2131","obj":"Tax:10090"},{"id":"A2132","pred":"tao:has_database_id","subj":"2132","obj":"Tax:10116"},{"id":"A2135","pred":"tao:has_database_id","subj":"2135","obj":"Tax:10090"},{"id":"A2136","pred":"tao:has_database_id","subj":"2136","obj":"MESH:D014867"},{"id":"A2139","pred":"tao:has_database_id","subj":"2139","obj":"MESH:D006973"},{"id":"A2140","pred":"tao:has_database_id","subj":"2140","obj":"MESH:D006973"},{"id":"A2141","pred":"tao:has_database_id","subj":"2141","obj":"MESH:D006973"},{"id":"A2142","pred":"tao:has_database_id","subj":"2142","obj":"MESH:D006973"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Although ACE2 pathway inhibition might lead to hypertensive effects, treatment with MLN-4760 for 4-5 weeks had no effect on blood pressure when administered 10 mg/kg/day in drinking water in wild type mice [117] nor in male (mRen2)27 transgenic hypertensive rats (administered 30 mg/kg/day subcutaneously via mini-osmotic pumps) [118], suggesting that hypertensive activity mediated by ACE2 inhibition is promptly balanced by compensatory mechanisms either in normal or hypertensive blood pressure conditions."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T727","span":{"begin":97,"end":100},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T728","span":{"begin":124,"end":129},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T729","span":{"begin":124,"end":129},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T730","span":{"begin":219,"end":223},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T731","span":{"begin":219,"end":223},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T732","span":{"begin":231,"end":233},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T733","span":{"begin":365,"end":373},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T734","span":{"begin":483,"end":488},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T735","span":{"begin":483,"end":488},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"}],"text":"Although ACE2 pathway inhibition might lead to hypertensive effects, treatment with MLN-4760 for 4-5 weeks had no effect on blood pressure when administered 10 mg/kg/day in drinking water in wild type mice [117] nor in male (mRen2)27 transgenic hypertensive rats (administered 30 mg/kg/day subcutaneously via mini-osmotic pumps) [118], suggesting that hypertensive activity mediated by ACE2 inhibition is promptly balanced by compensatory mechanisms either in normal or hypertensive blood pressure conditions."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T84420","span":{"begin":182,"end":187},"obj":"Chemical"},{"id":"T69860","span":{"begin":219,"end":223},"obj":"Chemical"}],"attributes":[{"id":"A75427","pred":"chebi_id","subj":"T84420","obj":"http://purl.obolibrary.org/obo/CHEBI_15377"},{"id":"A34156","pred":"chebi_id","subj":"T69860","obj":"http://purl.obolibrary.org/obo/CHEBI_30780"}],"text":"Although ACE2 pathway inhibition might lead to hypertensive effects, treatment with MLN-4760 for 4-5 weeks had no effect on blood pressure when administered 10 mg/kg/day in drinking water in wild type mice [117] nor in male (mRen2)27 transgenic hypertensive rats (administered 30 mg/kg/day subcutaneously via mini-osmotic pumps) [118], suggesting that hypertensive activity mediated by ACE2 inhibition is promptly balanced by compensatory mechanisms either in normal or hypertensive blood pressure conditions."}

{"project":"LitCovid-sentences","denotations":[{"id":"T283","span":{"begin":0,"end":509},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Although ACE2 pathway inhibition might lead to hypertensive effects, treatment with MLN-4760 for 4-5 weeks had no effect on blood pressure when administered 10 mg/kg/day in drinking water in wild type mice [117] nor in male (mRen2)27 transgenic hypertensive rats (administered 30 mg/kg/day subcutaneously via mini-osmotic pumps) [118], suggesting that hypertensive activity mediated by ACE2 inhibition is promptly balanced by compensatory mechanisms either in normal or hypertensive blood pressure conditions."}

{"project":"2_test","denotations":[{"id":"32708755-18235039-20678862","span":{"begin":207,"end":210},"obj":"18235039"},{"id":"32708755-20300067-20678863","span":{"begin":330,"end":333},"obj":"20300067"}],"text":"Although ACE2 pathway inhibition might lead to hypertensive effects, treatment with MLN-4760 for 4-5 weeks had no effect on blood pressure when administered 10 mg/kg/day in drinking water in wild type mice [117] nor in male (mRen2)27 transgenic hypertensive rats (administered 30 mg/kg/day subcutaneously via mini-osmotic pumps) [118], suggesting that hypertensive activity mediated by ACE2 inhibition is promptly balanced by compensatory mechanisms either in normal or hypertensive blood pressure conditions."}